Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.73 USD

51.73
1,388,647

+0.47 (0.92%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $51.74 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Moderna's (MRNA) Flu Vaccine Data Fails to Impress Investors

Moderna's (MRNA) early-stage flu vaccine data seems promising but it fails to meet investors' expectations.

Glaxo (GSK), Medicago COVID-19 Jab Effective Against Variants

Glaxo (GSK) and Medicago's plant-based vaccine achieves more than 70% efficacy rate against COVID-19 and its major variants.

Sanofi's (SNY) Filing for Rare Disease Drug Accepted by EMA

The EMA accepts Sanofi's (SNY) regulatory submission seeking approval for olipudase alfa, a potential treatment for acid sphingomyelinase deficiency.

Amicus (FOLD) Filings for AT-GAA in Pompe Disease Accepted by EMA

The European Medicines Agency accepts Amicus Therapeutics' (FOLD) MAA for AT-GAA, a potential treatment for Pompe disease.

The Zacks Analyst Blog Highlights: Visa, Broadcom, Morgan Stanley, Sanofi and MercadoLibre

The Zacks Analyst Blog Highlights: Visa, Broadcom, Morgan Stanley, Sanofi and MercadoLibre

Mark Vickery headshot

Top Analyst Reports for Visa, Broadcom & Morgan Stanley

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Broadcom Inc. (AVGO), and Morgan Stanley (MS).

Mirati (MRTX) to Begin Clinical Study in MTAP-Deleted Cancers

Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.

4 Reasons Why You Should Add Glaxo (GSK) to Your Portfolio

Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2021/2022, which should boost the top line in the long term

Mirati (MRTX) Beats on Q3 Earnings, Begins NDA Adagrasib Filing

Mirati's (MRTX) third-quarter earnings beat estimates. It initiates the NDA submission for adagrasib in second-line NSCLC. Shares rise in after-market trading.

Denali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss

Denali (DNLI) announces wider-than-expected loss per share for third-quarter 2021. Nonetheless, its shares rise following the announcement.

Regeneron (REGN) Q3 Earnings Beat, REGEN-COV Boosts Growth

Regeneron (REGN) beats on Q3 earnings while sales record strong year-over-year growth on the solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.

Novo Nordisk's (NVO) Q3 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) reports better-than-expected results for Q3. Sales are aided by growth in Diabetes and Obesity Care owing to higher GLP-1 revenues.

Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?

Regeneron's third-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.

Kinjel Shah headshot

Pharma Stock Roundup: Big Pharma Q3 Results, FDA Panel's Vote for PFE COVID Jab

Several big drugmakers announce third-quarter 2021 earnings. An FDA panel votes in favor of Pfizer's (PFE) COVID-19 vaccine for use in kids 5 to 11 years of age.

Alnylam's (ALNY) Q3 Earnings & Revenues Fall Shy of Estimates

Alnylam's (ALNY) earnings and sales miss estimates in the third quarter of 2021. The company reiterates its financial guidance for 2021. Stock down.

BioMarin (BMRN) Beats on Q3 Earnings, Ups 2021 Guidance

BioMarin's (BMRN) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company raises total revenue guidance and increases adjusted earnings guidance for 2021.

Sanofi (SNY) Q3 Earnings Beat, Sales Miss, 2021 EPS View Up

Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It raises earnings growth guidance range for the year.

Biotech Stock Roundup: BMY's Q3 Earnings Beat, MRNA's Vaccine Updates & More

Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.

Sheraz Mian headshot

Q3 Earnings Season Scorecard and Analyst Reports for Disney, Intel & Others

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Intel Corporation (INTC), and Medtronic plc (MDT).

Regeneron (REGN) Dupixent Meets Goal in Prurigo Nodularis Study

Regeneron's (REGN) phase III study on Dupixent for treating adults with uncontrolled prurigo nodularis meets its primary and all secondary endpoints.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters

J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.

Regeneron (REGN) Dupixent Gets FDA Nod for Asthma in Children

Regeneron (REGN) and Sanofi's (SNY) Dupixent secures FDA approval to treat children aged 6-11 years with moderate to severe asthma.

Will Moderna's (MRNA) COVID-Led Rally Continue in 2022?

Moderna's (MRNA) COVID-19 vaccine has boosted the company's prospects significantly since early 2020. Strong performance of the vaccine is likely to continue in 2022. However, competition seems to be on the rise.

4 Reasons to Add Regeneron (REGN) Stock to Your Portfolio

Regeneron (REGN) is expected to gain from a solid and diverse portfolio despite stiff competition for its key drugs. The promising pipeline also sets the stage for growth further.

Glaxo (GSK) Eyes Nod for Triumeq Expanded Use in Pediatric HIV

Glaxo (GSK) seeks approval for a new dispersible single-tablet regimen containing dolutegravir to treat children living with HIV.